Compare LSE & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSE | ACET |
|---|---|---|
| Founded | 2007 | 1947 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.7M | 71.3M |
| IPO Year | 2024 | N/A |
| Metric | LSE | ACET |
|---|---|---|
| Price | $4.30 | $0.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 4.7K | ★ 3.0M |
| Earning Date | 09-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $57,385,142.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.03 | $0.45 |
| 52 Week High | $14.99 | $1.11 |
| Indicator | LSE | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 39.06 | 39.37 |
| Support Level | $4.03 | $0.47 |
| Resistance Level | $4.62 | $0.52 |
| Average True Range (ATR) | 0.23 | 0.04 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 34.71 | 26.50 |
Leishen Energy Holding Co Ltd is a provider of clean-energy equipment and integrated solutions to the oil and gas industry, with a commitment to providing customers with high-performance, safe, and cost-effective energy solutions. The company's business segments include clean-energy equipment; oil and gas engineering technical services; new energy production and operation; and digitalization and integration equipment. A majority of its revenue is generated from the clean-energy equipment segment which supplies various equipments, such as reciprocating compressor units, expansion units, wellhead heating systems, wellhead safety control systems, oil-water separation systems, natural gas online sampling systems, oil and gas skid-mounted equipment, and polymer flexible composite pipes.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.